Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 9, 2026 135 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’... June 29, 2021 Trial Suggests Expanded Role for Blinatumomab in Treating ALL January 25, 2023 Helping Kids with Cancer Speak for the Supportive Care They Need December 13, 2024 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 Load more HOT NEWS How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... ESMO Calls on the European Commission to Fund Cancer Research and... Study Identifies Potential Drug Target to Prevent Some Liver Cancers 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend...
